2016: Addition of onalespib to crizotinib prior to progression in pts with ALK-pos NSCLC: P2 Results

Summary

Hsp90 is required for proper ALK function
Onalespib (AT13387) is a second generation Hsp90 inhibitor
Onalespib in ALK-driven pre-clinical models:
- Displays potent antitumor activity
- Delays the onset of resistance
In the clinic, onalespib
- Has a safety profile consistent with the class
- (diarrhea, mild transient visual changes)
- PK & PD results support weekly dosing
- – Has antitumor activity (PR) at a dose of 220 mg/m2 (D1,8,15 of 28 Day cycle)
Crizotinib (CZT) has demonstrated clinical activity in ALK-pos NSCLC
AT13387-05 is a 3-part, Phase 1-2 study in ALK-pos NSCLC
- Part A (Phase 1 of the study demonstrated the safety of Onalespib/CZT in combination with some activity in progressing patients
- Results are presented for Part B of the study, randomization to combination of Onalespib added to CZT vs CZT alone prior to development of resistance (Fig 2)

View further details below